MetaCap

Viking Therapeutics (VKTX) vs Xeris Biopharma (XERS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xeris Biopharma (XERS) has outperformed Viking Therapeutics (VKTX) over the past year, gaining 148.5% versus a loss of 27.7%. Over five years, XERS leads with a +682.0% price change compared with +360.4% for VKTX. Viking Therapeutics is the larger company by market cap ($3.16 billion vs $3.10 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

VKTX-27.70%XERS+148.46%
+158%+60%-38%
Nov 21, 20251 yearNov 20, 2026
VKTX+339.18%XERS+647.58%
+1485%+675%-134%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

VKTX versus XERS key metrics
MetricVKTXXERS
Share price$24.77$16.97
Market cap$3.16B$3.10B
1-day change-4.14%+2.11%
YTD return-29.59%+116.18%
1-year return-27.70%+148.46%
5-year return+360.41%+682.03%
Forward P/E—63.64
EPS (TTM)$-5.42$-0.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$291.85M
Revenue growth (YoY)—+43.72%
Net income (latest FY)$-359.64M$554.00K
Gross margin—85.41%
Operating margin—8.53%
Net margin—0.19%
52-week high$43.10$17.28
52-week low$23.82$5.25
Distance from 52-week high-42.53%-1.79%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+284.82%+1.89%
Average volume5.31M2.86M
Shares outstanding127.52M182.70M
Employees74435
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XERS has outperformed VKTX by 176.2 percentage points over the past year.

About Viking Therapeutics

VKTX stock →

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees

About Xeris Biopharma

XERS stock →

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees

VKTX vs XERS FAQ

Which is bigger, Viking Therapeutics or Xeris Biopharma?

Viking Therapeutics (VKTX) is larger, with a market capitalization of $3.16B compared with $3.10B for Xeris Biopharma (XERS).

Which stock has performed better over the past year, VKTX or XERS?

XERS returned +148.46% over the past 12 months, compared with -27.70% for VKTX (price return, excluding dividends). Past performance does not predict future results.

Are Viking Therapeutics and Xeris Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons